Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Endocrine Therapy With or Without Capecitabine in HR+/HER2- Advanced Breast Cancer
NCT07467330Phase 3Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2031
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Fujian Medical University Cancer Hospital. Started Nov 2025; status: recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07467330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07467330.